Last reviewed · How we verify
NCT03768518: GLP-1-CHI
GLP-1 Receptor Expression in CHI
trial testing 68Ga-exendin-4 PET/CT in Congenital Hyperinsulinism in 40 participants. Status unknown.
1 February 2019
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 7 February 2018 |
| Primary completion | 1 February 2019 |
| Estimated completion | 1 February 2019 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- 68Ga-exendin-4 PET/CT
Conditions studied
- Congenital Hyperinsulinism — all drugs for Congenital Hyperinsulinism →
Sponsor
Radboud University Medical Center
Who can join
Under 16, any sex, with Congenital Hyperinsulinism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of CHI patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03768518
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Congenital Hyperinsulinism
Currently open trials in the same condition.
- NCT06208215 — RZ358 Treatment for Congenital Hyperinsulinism · Phase 3 · active not recruiting
- NCT04732416 — HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) · Phase 2 · recruiting
- NCT03941236 — Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism · Phase 3 · active not recruiting
- NCT04205604 — 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism · Phase 2 · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03768518 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 7 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03768518.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing